Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Roche Holding AG (OTCQX International Premier:RHHBY)

33.20
Delayed Data
As of May 27
 +1.08 / +3.36%
Today’s Change
29.89
Today|||52-Week Range
38.54
-3.68%
Year-to-Date
Better Buy: Regeneron Pharmaceuticals, Inc. vs. Roche
May 27 / MotleyFool.com - Paid Partner Content
Ignore Intuitive Surgical, Inc.: Here Are 3 Better Stocks
May 23 / MotleyFool.com - Paid Partner Content
Cancer Immunotherapies Take Center Stage in Pre-ASCO Abstract Releases
May 26 / MotleyFool.com - Paid Partner Content
Roche Gets Accelerated Approval for Immunotherapy Drug
May 19 / Zacks.com - Paid Partner Content
Novartis Filing for MabThera Biosimilar Accepted in the EU
May 24 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close32.12
Today’s open33.20
Day’s range33.17 - 33.41
Volume1,157,861
Average volume (3 months)1,019,275
Market cap$183.8B
Dividend yield3.07%
Data as of 3:59pm ET, 05/27/2016

Growth & Valuation

Earnings growth (last year)-9.78%
Earnings growth (this year)--
Earnings growth (next 5 years)+8.30%
Revenue growth (last year)-3.39%
P/E ratio--
Price/Sales4.76
Price/Book10.80

Competitors

No competitors data available.

Financials

Last reporting dateJanuary 28, 2016
EPS forecast (this quarter)$0.90
Annual revenue (last year)$50.0B
Annual profit (last year)$9.2B
Net profit margin18.41%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chief Executive Officer &
Executive Director
Severin Schwan
COO-
Roche Diagnostics Division
Roland Diggelmann
Corporate headquarters
Basel, Basel-stadt (basle Town)

Forecasts

Partner Offers

Search for Jobs